Liver function may change how D-2570 works in the body
NCT ID NCT07715149
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This study tests how the experimental drug D-2570 moves through the body and whether it is safe in people with liver problems compared to those with healthy livers. Researchers will give a single dose of D-2570 to 24 adults aged 18 to 70 and measure drug levels in the blood over time. The goal is to understand if liver impairment affects how the drug is processed, which can guide future dosing recommendations.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- D-2570 tablet
- What this could lead to
- If successful, this study could help determine the right dose of D-2570 for people with liver problems, making future treatments safer.
- What could go wrong
- This is an early-stage, small study (24 people) focused on drug processing, not on treating a disease. Results may not predict effectiveness or safety in larger, diverse populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 24 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Voluntarily participate in this study and sign the written informed consent form after full informed consent, and agree to comply with the procedures specified in the study protocol. * Aged 18 to 70 years. * Both males and females are eligible. * Male participants must weigh no less than 50 kg, and female participants must weigh no less than 45 kg. * Participants with normal hepatic function must have adequate hematologic, renal, and hepatic function. * Have no plan to reproduce or donate sperm/eggs from screening until 30 days after the last dose of study drug, and agree to either completely abstain from sexual intercourse or use effective contraceptive measures from screening until 30 days after the last dose of study drug, as detailed in Appendix 3. Exclusion Criteria: * Have undergone any prior surgery that may affect drug absorption, distribution, metabolism, or excretion, which, in the opinion of the investigator, would make the participant unsuitable for enrollment. * Are female and currently lactating, or have a positive serum pregnancy test result at screening or during the study period. * Have a known history of drug or substance abuse, or test positive for drugs of abuse on the urine drug screen. * Have participated in another interventional clinical trial within 3 months prior to screening, or are currently participating in another clinical trial (participants who withdraw from a prior trial before treatment, i.e., were not randomized or did not receive study intervention, may be enrolled in this study). * Have received a live vaccine within 2 months prior to study drug administration, or intend to receive a live vaccine during the study period. * Have any other condition or finding that, in the opinion of the investigator, would make the participant unsuitable for participation in this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy adult participants are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The First Affiliated Hospital of Bengbu Medical University
RECRUITINGBengbu, Anhui, 233004, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Phase i clinical study to compare and evaluate the pharmacokinetics and safety of orally administered vorolanib tablets in participants with mild (Child-Pugh a) or moderate (Child-Pugh b) hepatic impairment and participants with normal hepatic function
- Effects of gastrocnemius kinesiology taping on postural control during Single-Leg stance in healthy adults
- Can a handheld eye test replace a lab machine?
- Can a single injection of HMB-003 be safe for humans? a first test begins
- Can VC005 mix safely with common drugs? a trial puts it to the test
- Brain training on the court: can tracking and imagery sharpen tennis skills?